The key facts

  • Researchers from the University of St Andrews analysed 50 online tests: from gut microbiome to a 'platinum check-up' costing £14,000
  • 16 tests promised life extension without evidence, 36 promised earlier diagnosis; only 15 explained possible drawbacks of testing
  • The ASA ruled that advertising for Voy's home testosterone test was misleading, linking fatigue and irritability to low testosterone

What the analysis of 50 tests showed

Researchers from the University of St Andrews in Scotland analysed 50 health tests advertised online: gut microbiome tests, blood markers, genetics, liver and lung function, cortisol levels, as well as pelvic and breast examinations, chest X-rays and ultrasound. Sellers included both online retailers and in-person clinics. Prices ranged from £6.99 (€8.36) for a home 'rapid kidney albumin test' to £14,000 (€16,751) for a 'platinum check-up' with multiple tests, imaging and a physical examination; some clinics added a luxury hotel or spa package, and advertising for other tests was promoted by celebrities and influencers.

Unsubstantiated promises and lack of warnings

According to the study, published in the journal BMJ Open, many tests made unsubstantiated claims or offered screening not recommended by national health authorities. Sixteen tests claimed without evidence that they would help people live longer, 36 promised earlier diagnosis and better health outcomes, and only 15 explained the potential downsides of testing — inaccuracy or the risks of intimate examinations. In one example, a retailer cited mortality from a specific disease, stating that sufferers 'could have been detected by one of our… health checks. Just think how many of them could be alive today.' Among the 50 sellers, 14 offered testicular screening, 13 breast screening and 9 pelvic examinations to people without worrying symptoms, although the UK's National Health Service does not recommend such tests for everyone.

The Voy case and conclusions on regulation

A separate example of weak regulation was the advertising of a home testosterone blood test from the online provider Voy, which sells testosterone preparations, menopause remedies and weight-loss products. The UK advertising regulator ASA ruled it misleading: the advert linked common symptoms, such as fatigue and irritability, to low testosterone, pushing men to buy the kit. Voy objected that the advert did not claim low testosterone was the only explanation for the symptoms, but the regulator ruled against the company, ordering it not to exaggerate the link. The study's authors noted that few such cases reach the regulators and called this 'a regulatory gap and a patient safety issue.' They acknowledged that home tests can fill gaps in the healthcare system, but only if based on evidence: poor-quality screening leads to false positives ('false alarms'), false negatives ('false reassurance') and the loss of personal money with almost no benefit.